Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy

被引:16
|
作者
Monnier, L. [1 ]
Colette, C. [1 ]
Dejager, S. [2 ]
Owens, D. R. [3 ]
机构
[1] Univ Montpellier, Inst Clin Res, 641 Ave Doyen Giraud, F-34093 Montpellier 5, France
[2] Hosp Pitie Salpetriere, Dept Endocrinol, Paris, France
[3] Swansea Univ, Diabet Res Grp, Swansea, W Glam, Wales
来源
关键词
Glucose homeostasis; Quality of diabetes therapy; GLYCEMIC VARIABILITY; MICROVASCULAR COMPLICATIONS; CARDIOVASCULAR OUTCOMES; DAWN PHENOMENON; PLASMA-GLUCOSE; VASCULAR COMPLICATIONS; MYOCARDIAL-INFARCTION; RECEPTOR AGONISTS; OXIDATIVE STRESS; BLOOD-GLUCOSE;
D O I
10.1007/s11154-016-9325-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Achieving near normal glucose homeostasis implies that all components of dysglycemia that are present in diabetes states be eliminated. Reducing ambient/overall hyperglycemia is a pre-requisite to eliminate the risk of development and progression of diabetes complications. More controversially however, are the relative and related contributions of postprandial glucose excursions, glucose variability, hypoglycemia and the dawn phenomenon across the spectrum of dysglycemia. For instance, it is likely that the dawn phenomenon contributes to ambient hyperglycemia and that postprandial glucose excursions are at the cross road of ambient hyperglycemia and glucose variability with glucose fluctuations as causative risk factors for hypoglycemia. Proof-of-concept trials such as the ongoing FLAT-SUGAR study are necessary for gaining further insight into the possible harmful effects of some of these features such as excessive glycemic variability and glucose excursions, still considered to be of minor relevance by several diabetologists. Whether their role will be more thoroughly proven through further intervention trials with "hard" endpoints, remains to be seen. In the meantime more consideration should be given to medications aimed at concomitantly reducing ambient/overall hyperglycemia and those additional abnormal glycemic features of dysglycemia.
引用
收藏
页码:91 / 101
页数:11
相关论文
共 50 条
  • [1] Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy
    L. Monnier
    C. Colette
    S. Dejager
    D. R. Owens
    Reviews in Endocrine and Metabolic Disorders, 2016, 17 : 91 - 101
  • [2] HbA1c or glucose for diabetes diagnosis?
    Florkowski, CM
    Woltersdorf, WWW
    ANNALS OF CLINICAL BIOCHEMISTRY, 2005, 42 : 408 - 409
  • [3] HbA1c or glucose for diabetes diagnosis?
    Kilpatrick, ES
    ANNALS OF CLINICAL BIOCHEMISTRY, 2005, 42 : 165 - 166
  • [4] Value of HbA1c for diabetes screening in subjects with normal fasting glucose
    Kim, So-Young
    Kang, Sun-Mi
    Jin, Heung-Yong
    Park, Tae-Sun
    Baek, Hong-Sun
    Park, Ji-Hyun
    DIABETES, 2008, 57 : A555 - A556
  • [5] HbA1c and blood glucose for the diagnosis of diabetes
    Misra, Anoop
    Garg, Satish
    LANCET, 2011, 378 (9786): : 104 - 106
  • [6] Glucose Variability (GV) in Type 1 Diabetes (DM1) Patients with Near-Target HbA1c Level
    Patrakeeva, Evgeniya M.
    Gorbunova, Elena
    Peshkova, Elena
    Posrednikova, Ksenia
    Zalevskaya, Alsu G.
    Shlyakhto, Evgeniy V.
    DIABETES, 2010, 59 : A543 - A544
  • [7] Screening diabetes with HbA1c and fasting plasma glucose
    Yang, T.
    Yu, D.
    Zhou, H.
    Zhu, G.
    DIABETOLOGIA, 2010, 53 : S158 - S158
  • [8] Inequity of diagnosis of diabetes by plasma glucose and HbA1c
    Saiedullah, M.
    Rahman, M. R.
    Khan, M. A. H.
    BANGLADESH JOURNAL OF MEDICAL SCIENCE, 2011, 10 (04): : 284 - 286
  • [9] Normal HbA1c in diabetes is not necessarily a benign entity
    Wallace, TM
    Beatty, SA
    Matthews, DR
    DIABETES, 2002, 51 : A483 - A483
  • [10] Defining the relationship between plasma glucose and HbA1c -: Analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial
    Rohlfing, CL
    England, JD
    Wiedmeyer, HM
    Tennill, A
    Little, RR
    Goldstein, DE
    DIABETES CARE, 2002, 25 (02) : 275 - 278